Cerebrolysin: effects, research and approval status
Clinical review pending
What Cerebrolysin is, what stroke and dementia studies have found, and the uncertainties around benefits, risks and US approval.
Does Cerebrolysin help after a stroke, with dementia or after a brain injury? Human studies have not yet established a clear benefit. Some studies report improvements in particular functions, but reviews assess the findings cautiously. In acute ischemic stroke, where a blocked vessel interrupts the brain’s blood supply, Cerebrolysin may also increase the risk of serious nonfatal adverse events. 5
What is Cerebrolysin?
Cerebrolysin is made from pig brain tissue. The preparation contains low-molecular-weight peptides, or short chains of protein building blocks, along with free amino acids. It is also known as Cere and FPF-1070. The mixture’s precise composition is not fully defined.
In several countries, Cerebrolysin is approved and used as an injectable preparation for conditions such as stroke, dementia and traumatic brain injury. It is also marketed for improving mental performance. It is not approved in the United States.
How does it work?
Cerebrolysin is intended to act like the body’s own neurotrophic factors: signals that help nerve cells survive and function. The following effects have been observed in laboratory and animal models:
- It protected nerve cells from damage, an effect described as “neuroprotective.” 1
- It inhibited programmed cell death, known as apoptosis. 2
- It protected against damage caused by excessive nerve-cell excitation, an effect described as “anti-excitotoxic.” 3
Which components of the complex mixture are active, and how they work, are not fully understood. Findings from laboratory and animal models describe possible mechanisms. They do not yet establish that treatment improves human health.
Is Cerebrolysin FDA-approved?
No. The US Food and Drug Administration has not approved Cerebrolysin. It is also not listed as an FDA-recognized substance for the individualized preparation of medicines, known as compounding. It is used clinically in more than 50 countries, including parts of Europe, Russia and the Commonwealth of Independent States, China and South Korea. Uses include stroke, dementia and brain injury. Clinical use and formal approval are not the same thing. 4
What does the research show?
Clinical trials present a mixed picture. Interpretation depends on what each study measured: mortality, mental abilities and the ability to manage everyday life are different outcomes.
| Review | Finding | Certainty of the evidence |
|---|---|---|
| Systematic Cochrane review 5 of acute ischemic stroke | No demonstrated beneficial effect on mortality; potentially more serious nonfatal adverse events. Many studies received manufacturer support. | Moderate-certainty evidence for the mortality finding |
| Separate Cochrane review 6 of vascular dementia | Signs of improvements in cognitive abilities and overall functioning; any effect may, however, be too small to be clinically meaningful. | Very low-quality evidence |
| Independent analysis 7 of brain-derived nootropics, preparations intended to improve mental function | Similarly cautious conclusions | Low certainty |
It therefore remains unclear whether the improvements seen in individual studies amount to a reliable benefit that people can notice in everyday life.
Frequently asked questions
Is Cerebrolysin FDA-approved?
No. As of September 2026, Cerebrolysin is not FDA-approved for any use. Although it is used clinically in more than 50 countries, this does not confer approval in the US. 8 There is no regular pharmaceutical distribution route for Cerebrolysin there.
Is Cerebrolysin legal in the United States?
Cerebrolysin is not lawfully marketed for human use in the United States; there is no FDA-approved product. A permitted route through compounding is also not established here for this proprietary preparation derived from pig tissue. Importation for personal use carries legal and health risks.
This does not establish that every form of access outside a registered clinical trial is prohibited without exception. Possible exceptions have not been clarified.
Can a doctor prescribe Cerebrolysin in the US?
There is no regular prescription route for an FDA-approved Cerebrolysin product. Permitted access through compounding is also not established here. Whether doctors may prescribe or dispense the preparation under particular legal provisions remains unresolved. A blanket statement that this is prohibited in all circumstances would therefore go too far.
Does Cerebrolysin actually work?
A clear benefit has not yet been established in human studies. Manufacturer-funded trials such as CARS reported better arm function after stroke. 9 The CAPTAIN trial series reported a small-to-moderate benefit after traumatic brain injury. 10
The independent Cochrane review of acute ischemic stroke, last updated in 2023, found moderate-certainty evidence of no beneficial effect on mortality. Cerebrolysin may also increase the risk of serious nonfatal adverse events. 5
These findings answer different questions. Better arm function, for example, says nothing about whether a treatment reduces mortality. There are methodological uncertainties too. The Cochrane authors rated the risk of bias in a large share of the stroke studies as unclear or high. 5
How does Cerebrolysin differ from a peptide supplement?
Cerebrolysin is a pharmaceutical extract for injection, not a dietary supplement. One company makes the proprietary preparation: EVER Neuro Pharma in Austria. In countries where it has the relevant approval, it is used in clinical settings. 11
Peptide supplements sold without a prescription, by contrast, are taken by mouth. They differ from Cerebrolysin in chemical composition, legal classification and clinical use. The shared word “peptide” does not make the products comparable.
What did the Cochrane review of Cerebrolysin find?
The 2023 systematic Cochrane review brought together seven randomized controlled trials involving a total of 1,773 participants with acute ischemic stroke. In these trials, chance determines which treatment group each participant joins. One trial studied a similar preparation called Cortexin. 5
For all-cause mortality, the review found moderate-certainty evidence of no beneficial effect. The risk ratio (RR) was 0.96, with a 95% confidence interval (CI) from 0.65 to 1.41. The RR describes the risk in the treatment group relative to the comparison group. The wide confidence interval shows how uncertain the precise effect size is: the estimate is compatible with both lower and higher mortality.
For serious nonfatal adverse events, the findings suggested increased risk: RR 2.39, 95% CI 1.10 to 5.23. This analysis was based on 3 trials involving 1,335 participants. Here too, the estimate was imprecise, as the wide confidence interval indicates. 5
The review first appeared in 2010. The 2020 update was followed by the 2023 version.
Why is Cerebrolysin approved in so many countries if the evidence is uncertain?
Approval in one country does not mean the FDA also recognizes the preparation. Nor does it resolve the methodological questions independent reviewers have raised about the studies.
Different approval dates, evidence requirements and assessments of the available data could explain differences between countries. Whether that was actually the case for Cerebrolysin, and what role limited treatment options played, is not established here.
Sources
- Sources: Cochrane systematic reviews of cerebrolysin in acute ischemic stroke (Ziganshina et al., 2023, DOI: 10.1002/14651858.CD007026.pub7 5) and vascular dementia (Chen et al., 2019, DOI: 10.1002/14651858.CD008900.pub3 6), an independent review (Alsulaimani and Quinn, 2021, DOI: 10.1016/j.cccb.2021.100012 7), and animal studies of neuroprotection (Huang et al., 2014, DOI: 10.1016/j.kjms.2014.02.009 1), apoptosis (Rockenstein et al., 2006, DOI: 10.1007/s00401-006-0166-5 2), and excitotoxicity (Veinbergs et al., 2000, DOI: 10.1007/978-3-7091-6781-6_29 3), all indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product. Original reference Original reference Original reference Original reference Original reference Original reference